151-160 of 1,788 results

  • A quote in green text against a white background reads, "The math is conclusive: Major cuts to Medicaid are the only way to meet the House’s budget resolution requirements. There are a myriad of options available for cutting Medicaid, but all of them would leave the states facing  difficult choices to raise revenues or cut spending."

    The Math is Conclusive: Major Medicaid Cuts Are the Only Way to Meet House Budget Resolution Requirements

    Quick Insights

    The CBO letter confirms early expectations, finding that over the next 10 years, 93% of non-Medicare spending in the E&C [House Energy & Commerce Committee] jurisdiction is from the federal share of Medicaid spending…Even if E&C eliminated all non-Medicaid and CHIP spending, the committee would need to cut federal spending on Medicaid and CHIP by well over $700 billion, nearly 10% of projected spending.

  • As COVID-19 Divisions, Attacks, and Misinformation Take Their Toll, Less Than Half of the Public Is Confident That the CDC and FDA Can Carry Out Core Functions 

    News Release

    Five years after the start of  COVID-19 pandemic and the communications challenges, divisions, and false claims that followed, less than half of the public say they have at least some confidence in the federal government’s health agencies like the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) to carry out many of their core responsibilities, a new KFF Tracking Poll on Health Information and Trust finds.The low levels of…

  • Vice President Harris’ Proposal to Broaden Medicare Coverage of Home Care

    Issue Brief

    On October 8, 2024, Vice President Harris has proposed to expand Medicare to provide home care to help families who are struggling with the costs of long-term care. If enacted, this would be the first major expansion of Medicare since the Medicare Modernization Act of 2003 that added a prescription drug benefit to the program.

  • KFF Health Tracking Poll May 2024: Voters’ Views of Health Policy Issues in Context of Presidential Campaigns

    Feature

    Voters are split largely along partisan lines in terms of who they trust in regard to various health care issues, but Biden captures more than Trump trust from Independent voters. Biden is also more trusted by older adults when it comes to entitlement programs. Voters are still largely unaware of the drug pricing provisions of the Inflation reduction Act. Large majorities of voters, particularly Democratic voters, support a federal right to abortion.

  • Key Facts About Medicare Part D Enrollment, Premiums, and Cost Sharing in 2024

    Issue Brief

    This brief analyzes 2024 Medicare Part D enrollment, premiums, and cost sharing. The analysis highlights the continued growth in Medicare Advantage enrollment in the Part D marketplace and substantially higher average monthly premiums for stand-alone Part D drug plan coverage. Changes to the Part D benefit included in the Inflation Reduction Act are helping to lower out-of-pocket costs for patients but could also contribute to higher-priced Part D coverage.

  • 2025 California Health Benefits Survey

    Report

    The survey provides an in-depth look at trends in employer-sponsored coverage in California, including premiums, cost sharing, offer rates, and employer strategies to manage costs and access to care, including comparisons to the nation overall.

  • In his latest column, KFF’s President and CEO Drew Altman discusses how the low levels of trust in the CDC and FDA today seen in KFF’s recent survey findings present a danger should the country face another epidemic.

    The Sad State of Trust in the CDC and FDA

    From Drew Altman

    In his latest column, KFF’s President and CEO Drew Altman discusses how the low levels of trust in the CDC and FDA today seen in KFF’s recent survey findings present a danger should the country face another epidemic.

  • Insurer Strategies to Control Costs Associated with Weight Loss Drugs

    Issue Brief

    Affordable Care Act (ACA) Marketplace plans rarely cover GLP-1 drugs approved solely for obesity treatment, according to a an analysis of 2024 federal plan data. Wegovy, a drug that is approved for weight loss, is covered by just 1% of Marketplace prescription drug plans, compared to 82% of Marketplace prescription drug plans for Ozempic, which contains the same active ingredient as Wegovy (semaglutide) but is approved only for diabetes. This analysis examines publicly available formularies…